Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Inhibikase Therapeutics (IKT) Other financing activities (2024)

Inhibikase Therapeutics (IKT) has disclosed Other financing activities for 1 consecutive years, with -$30608.0 as the latest value for Q1 2024.

Quarterly Other financing activities changed N/A to -$30608.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was -$30608.0 through Mar 2025, changed N/A year-over-year, with the annual reading at -$138556.0 for FY2023, N/A changed from the prior year.
Other financing activities for Q1 2024 was -$30608.0 at Inhibikase Therapeutics.
The five-year high for Other financing activities was -$30608.0 in Q1 2024, with the low at -$30608.0 in Q1 2024.